MMP9 and breast carcinoma: Furthermore, HSP might have the prospective to be developed as a co-chemotherapeutic agent combination with doxorubicin resulted in arresting cell cycle, induce apoptosis, suppressed Rac1, HER2, MMP9 expression, and cell migration in HER2 overexpressing breast cancer cells respective doses of 95 μM and 0.2 μM, where dose were 377 and 0.8 μM, respectively during individual testing [61].